Open Access

ARTICLE

Serum interferon-beta level determined by an ultrasensitive electrochemiluminescence immunoassay is increased in clinically active and inactive systemic lupus erythematosus

Karim Dorgham¹, Omaira Da Mata Jardin¹, Clara Mellot^1,2, Suzanne Mouries-Martin^1,2, Maude Calixte^1,2, Ngoc Khanh Nguyen¹, Raphael Lhote², Julien Haroche^1,2, Fleur Cohen-Aubart^1,2, Micheline Pha², Miguel Hié², Matthias Papo², François Chasset^1,2,3, Pascale Ghillani-Dalbin⁴, Hans Yssel¹, Zahir Amoura^1,2, Guy Gorochov^1,4, Alexis Mathian^1,2

1 Sorbonne Université, Inserm, centre d’immunologie et des maladies infectieuses (Cimi-Paris), Paris, France
2 Groupement hospitalier Pitié-Salpêtrière, AP-HP, centre de référence des maladies auto-immunes et auto-inflammatoires systémiques rares de l’adulte d’Ile-de-France, Centre et Martinique, service de médecine interne 2, Institut E3M, Paris, France
3 Sorbonne Universitéé, service de dermatologie et allergologie, Hôpital Tenon, AP-HP, Paris, France
4 Département d’immunologie, groupement hospitalier Pitié-Salpêtrière, AP-HP, Paris, France

* Corresponding Author: Karim Dorgham,

European Cytokine Network 2025, 36(2), 15-23. https://doi.org/10.1684/ecn.2025.0502

Accepted 01 May 2025;

Abstract

Background: Type I interferons, which play an important role in the pathogenesis of various autoimmune diseases such as systemic lupus erythematosus (SLE), are expressed at very low levels under physiological conditions. In this study, we focused on IFN-beta (IFN-β) for its potential use as a biomarker of SLE activity and compared three different technologies for its quantification in the serum of healthy donors and patients with SLE. Methods: A total of 93 serum samples from healthy donors and 463 serum samples from lupus patients were tested using either ELISA, digital ELISA based on Single Molecule Array (Simoa®) technology, or a novel ultrasensitive immunoassay (S-Plex®) based on electrochemiluminescence. Results: Circulating IFN-β levels were detected in 1.3%, 6.7%, and 100% of healthy donors by Simoa, ELISA, and S-Plex technology, respectively. In patients with SLE, circulating IFN-β levels were detected in 7.5%, 18.8%, and 98.3% by Simoa, ELISA, and S-Plex technology, respectively, demonstrating the utility of the S-Plex technology for quantifying this cytokine in serum. S-Plex-determined serum IFN-β concentrations were higher in patients with SLE than in healthy donors (median, 0.297 pg/mL vs 0.205 pg/ mL, p=0.0004, respectively), in patients with active SLE compared to those with inactive SLE (0.389 pg/mL vs 0.243 pg/mL, p=0.0013, respectively), in patients with severe flare compared to those without flare (0.462 pg/mL vs 0.244 pg/mL, p=0.0009, respectively), and in patients not in remission compared to those in remission (0.374 pg/mL vs 0.239 pg/mL, p=0.0027, respectively). However, according to ROC curve analyses, S-Plex- determined serum IFN-β levels demonstrated poor diagnostic performances for distinguishing disease clinical status in SLE. Conclusion: Using S-Plex technology, circulating IFN-β levels are quantifiable in the serum of healthy donors and are significantly higher in patients with SLE. They increase significantly in patients with clinically active disease. Although IFN-β is a biomarker of SLE activity, its serum levels in patient groups show considerable overlap, making it difficult to reliably distinguish between different states of disease activity.

---

Keywords

---